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shape (see Figure). Other important features of this loop final fold only after ligand binding, with the ligand being
are the base triple U16-C18-G110 (shown in orange) and an essential part of the structure. In the absence of
the U-turn U16 to C18. The upper asymmetric internal the ligand, the RNA is rather unstructured. This ligand-
loop forms a series of S-turns that span residues C5 to dependent structural stabilization prompted the design
G13. Both of the internal loops zipper up and stack with of a translation regulation system. Aptamers were in-
the central stem, forming a tight structure surrounding serted into the 5 untranslated leader of messenger
the streptomycin binding pocket, which is located in the RNAs without affecting their expression. Only after addi-
elbow of the L shape. The tight interlocking of both tion of the ligand did the RNA fold, leading to repression
the upper and lower internal loops is stabilized by a of translation [7]. Since this discovery, many of us have
magnesium ion interacting with residues U10-11 from wondered why nature did not make use of such a clever
the upper loop and residue C109 of the lower loop (indi- mechanism. Several years since researchers developed
cated as M1 in the Figure). Residue C109 itself is in- this regulatory concept, it was discovered that this
volved in a noncanonical base pair with G12. mechanism is indeed used by nature. Metabolite binding
The antibiotic binding pocket is an elaborate structure domains in mRNAs, which refold after ligand binding,
in which walls are formed by bases from both interlocked were recently found for cyanocobalamin, thiamine, and
loops. The streptose ring of streptomycin is buried FMN [8]. These recent findings give us a taste of what
deeply in the pocket and makes contacts with multiple is waiting to be discovered and clearly show that metab-
residues, in particular residues at positions U11 and G12 olite-RNA complexes will be used in the future for a
from the upper loop and residues U16 and U17 from the yet unpredictable number of applications. We can now
lower loop. In contrast to the streptomycin-ribosome predict that many biosynthetic pathways will be regu-
structure, most RNA-antibiotic contacts in the aptamer lated by metabolite binding “natural aptamers,” and we
involve base edges and not backbone phosphates. Rec- might even find a structure similar to the streptomycin
ognition between the antibiotic and the RNA is predomi- aptamer in a bacterium producing streptomycin.
nantly achieved through hydrogen bonds, one of which
is mediated through a bridging water molecule. All of
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bacteria by binding tightly to the acceptor site (A site)
on the 30S subunit of the ribosome and consequently
inhibit bacterial protein synthesis. As is the case for all
the other compounds classes of antibacterials, resis-
In this issue of Chemistry & Biology, Wright and col- tance to these drugs has increased rapidly with usage.
leagues report an elegant method for inhibiting en- In aminoglycoside-producing organisms, resistance to
zymes critical for rendering bacteria drug resistant. the compound results from the methylation of nucleo-
By using cationic peptides as inhibitors, the authors tides at the A site in the ribosome, preventing the drug
have exploited two antibacterial mechanisms, making from binding due to steric and electrostatic interference.
For the notorious pathogen Mycobacterium tuberculo-it doubly difficult for microbial retaliation.
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sis, resistance results from single nucleotide changes peptide- and enzyme-dependent. This will only be re-
solved by elucidation of the high-resolution structuresin the 16S rRNA of the ribosome (this organism has only
a single copy of the corresponding gene) or the S12 of the complexes.
Using the indolicidin analog CP10A as a starting point,small ribosomal subunit protein [2]. In addition, drug
efflux is a newly discovered mechanism that is certain the authors prepared a series of truncated peptides and
measured their inhibitory activity against both theto become more relevant to aminoglycoside resistance
[3]. However, for essentially all other microorganisms, N-acetyltransferases and O-phosphotransferases. They
were able to clearly define the N-terminal portion of thehigh-level clinical resistance results from the expression
of genes with one of three catalytic activities: ATP- peptide as the most critical portion required for binding;
however, surprisingly, they also showed that the posi-dependent O-phosphorylation, O-nucleotidylation, or
acetyl-CoA-dependent N-acetylation [4]. These en- tion of the charged residues within the peptide was
relatively unimportant in determining inhibitory strength.zymes covalently modify the drug, resulting in com-
pounds with substantially weaker affinities for their ribo- These synthetic derivatives of CP10A open the way to a
more detailed analysis of structure-activity relationshipssomal RNA target and, ultimately, in drug resistance [5].
In the article by Wright and colleagues published in this within a defined peptide scaffold. Whether these syn-
thetic peptides also exhibit antibacterial activity remainsissue, the authors have taken a tantalizing step closer
to “resisting resistance” [10]. The authors have focused to be determined.
This work presents an obvious paradigm for devel-their research on members of both the aminoglycoside
O-phosphotransferase and aminoglycoside N-acetyl- oping clinical inhibitors of aminoglycoside-modifying
enzymes. The coadministration of a -lactam andtransferase families for almost a decade and have ap-
plied a combination of approaches to dissect these en- -lactamase inhibitor (e.g., Augmentin) is extremely
effective in treating bacterial infections that do not re-zymes’ structure, function, and mechanism. Particularly
noteworthy in this regard was this group’s observation spond to a -lactam antibiotic alone. Nearly 100 different
aminoglycoside-modifying enzymes have been de-that these antibiotic-modifying enzymes are functional
and structural relatives of mammalian serine/threonine scribed that are both laboratory and clinically derived.
In addition to the three classes of modifying enzymes,kinases and histone acetyltransferases [6, 7], and in
the case of the aminoglycoside O-phosphotransferase, members of each family exhibit an absolute regioselec-
tivity in their modifying activity. This initially implies thatwortmannin, a known inhibitor of protein kinases, was
shown to inhibit the activity of the enzyme [8]. Since overcoming resistance by inhibiting the modifying en-
zymes would be a nearly impossible task. However, theboth the mammalian homologs of aminoglycoside
O-phosphotransferases and N-acetyltransferases natu- highly negatively charged aminoglycoside binding sites
of both the N-acetyltransferases and O-phosphotrans-rally act on proteins, the key question was whether pep-
tides could be identified that would bind to the aminogly- ferases and the similarities observed between these two
classes of aminoglycoside-modifying enzymes with pro-coside modifying enzymes and inhibit their activity.
The chemical structures of the aminoglycosides gave tein kinases and histone acetyltransferases suggested
to the authors that cationic peptides might exhibit botha strong hint that positively charged peptides would be
the best inhibitors. Furthermore, the three-dimensional tight binding and, more importantly, a broad spectrum of
inhibitory activity against many, or all, aminoglycoside-structures of both aminoglycoside N-acetyltransferases
and O-phosphotransferases revealed a highly nega- modifying enzymes. They have shown this conclusively
and elegantly.tively charged active site which would most likely ac-
commodate these polycationic antibiotics (remember Finally, as noted earlier, bacteria will inevitably find
ways to generate resistance to toxic, bactericidal com-they bind with nanomolar affinity to rRNA). In addition,
a number of cationic peptides have been identified from pounds. However, the combined activity of cationic pep-
tides as inhibitors of aminoglycoside-modifying en-vertebrates and insects that have antibacterial activity,
including the cecropins, pyrrhocoricins, maganins, and zymes and their intrinsic antibacterial activity argues
that resistance to these compounds is unlikely to occurindolicidins (reviewed in [9]). Many of these peptides
exert their antibacterial effects by binding to the lipo- in a single genetic transformation. Any genetic event
that would reduce the peptide’s affinity for its aminogly-polysaccharide outer membrane component of gram-
negative organisms and either forming pores or gaining coside-modifying enzyme target may reduce the effi-
cacy of the aminoglycoside as an enzyme substrateaccess to the cytoplasm, where they act on other tar-
gets. In this study, a number of these cationic antimicro- but, importantly, would leave the intrinsic antibacterial
activity of the peptide unchanged. Similar argumentsbial peptides were tested as inhibitors against two differ-
ent aminoglycoside N-acetyltransferases (AAC(6)-Ii and can be made for mutations affecting the target of the
antibacterial action of the cationic peptides. Therefore,e) and two different O-phosphotransferases (APH(2)-Ia
and APH(3)-IIIa). These results demonstrated a signifi- multiple independent mutations would be necessary to
generate insensitivity of the peptide for both its intrinsiccant degree of selectivity, with certain peptides exhib-
iting striking inhibitory specificity against a single en- target and aminoglycoside-modifying enzyme. Statisti-
cally, such an event is extremely unlikely.zyme, and others showing a broader range of inhibitory
activity. They also differed in the type of inhibition that The discovery and development of therapeutic anti-
bacterial compounds by the academic and pharmaceu-was observed, with some peptides exhibiting competi-
tive inhibition versus aminoglycoside substrate (e.g., tical communities ranks as one of the most important
contributions to human health in the last 100 years. TheAAC(6)-Ii), and others exhibiting noncompetitive inhibi-
tion versus aminoglycoside substrates, suggesting that enormous increase in clinical resistance to all classes
of antibacterial compounds in the last decade hasalternative binding modes are present that are both
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